JP2017529851A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017529851A5 JP2017529851A5 JP2017516350A JP2017516350A JP2017529851A5 JP 2017529851 A5 JP2017529851 A5 JP 2017529851A5 JP 2017516350 A JP2017516350 A JP 2017516350A JP 2017516350 A JP2017516350 A JP 2017516350A JP 2017529851 A5 JP2017529851 A5 JP 2017529851A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cells
- car
- cell
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 claims 22
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 19
- 210000004027 cell Anatomy 0.000 claims 11
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 9
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 9
- 102000010956 Glypican Human genes 0.000 claims 8
- 108050001154 Glypican Proteins 0.000 claims 8
- 108050007237 Glypican-3 Proteins 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- 210000002865 immune cell Anatomy 0.000 claims 7
- -1 CD8α Proteins 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 230000011664 signaling Effects 0.000 claims 5
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 4
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 4
- 102000040430 polynucleotide Human genes 0.000 claims 4
- 108091033319 polynucleotide Proteins 0.000 claims 4
- 239000002157 polynucleotide Substances 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 208000006332 Choriocarcinoma Diseases 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 208000008938 Rhabdoid tumor Diseases 0.000 claims 1
- 206010073334 Rhabdoid tumour Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000003874 Simpson-Golabi-Behmel syndrome Diseases 0.000 claims 1
- 208000008383 Wilms tumor Diseases 0.000 claims 1
- 208000012018 Yolk sac tumor Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 210000004544 dc2 Anatomy 0.000 claims 1
- 208000001991 endodermal sinus tumor Diseases 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 201000008026 nephroblastoma Diseases 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000003289 regulatory T cell Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462055979P | 2014-09-26 | 2014-09-26 | |
| US62/055,979 | 2014-09-26 | ||
| PCT/US2015/052227 WO2016049459A1 (en) | 2014-09-26 | 2015-09-25 | Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017529851A JP2017529851A (ja) | 2017-10-12 |
| JP2017529851A5 true JP2017529851A5 (enExample) | 2018-11-08 |
Family
ID=55582053
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516350A Pending JP2017529851A (ja) | 2014-09-26 | 2015-09-25 | 養子免疫療法のためのグリピカン−３特異的キメラ抗原レセプター |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20170281683A1 (enExample) |
| EP (2) | EP3198010B1 (enExample) |
| JP (1) | JP2017529851A (enExample) |
| DE (1) | DE20196219T1 (enExample) |
| ES (2) | ES2851123T1 (enExample) |
| WO (1) | WO2016049459A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3014001A1 (en) | 2016-02-25 | 2017-08-31 | Cell Medica Switzerland Ag | Binding members to pd-l1 |
| WO2018018958A1 (en) * | 2016-04-22 | 2018-02-01 | Carsgen Therapeutics Co., Ltd. | Compositions and methods of cellular immunotherapy |
| CA3031846A1 (en) | 2016-07-26 | 2018-02-01 | Tessa Therapeutics Pte. Ltd. | Chimeric antigen receptor |
| KR20250072712A (ko) | 2016-12-02 | 2025-05-26 | 앤젤레스 테라퓨틱스, 인코포레이티드 | 합성 면역 수용체 및 이의 사용 방법 |
| JP2018093823A (ja) * | 2016-12-15 | 2018-06-21 | Ｈｅａｒｔｓｅｅｄ株式会社 | 未分化幹細胞除去剤及び未分化幹細胞除去方法 |
| TWI780102B (zh) * | 2017-01-10 | 2022-10-11 | 國立大學法人山口大學 | 抗gpc3抗體 |
| SG10201913582XA (en) | 2017-04-26 | 2020-02-27 | Eureka Therapeutics Inc | Constructs specifically recognizing glypican 3 and uses thereof |
| EP3441461A1 (en) * | 2017-08-11 | 2019-02-13 | Baylor College of Medicine | Cd1d-restricted nkt cells as a platform for off-the-shelf cancer immunotherapy |
| US20220403001A1 (en) | 2018-06-12 | 2022-12-22 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| WO2019246563A1 (en) | 2018-06-22 | 2019-12-26 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| US20210261646A1 (en) * | 2018-07-03 | 2021-08-26 | Sotio, LLC | Chimeric receptors in combination with trans metabolism molecules enhancing glucose import and therapeutic uses thereof |
| WO2020017479A1 (ja) * | 2018-07-17 | 2020-01-23 | ノイルイミューン・バイオテック株式会社 | 抗ｇｐｃ３一本鎖抗体を含むｃａｒ |
| SG11202101284UA (en) | 2018-08-14 | 2021-03-30 | Sotio Llc | Chimeric antigen receptor polypeptides in combination with trans metabolism molecules modulating krebs cycle and therapeutic uses thereof |
| BR112021006254A2 (pt) | 2018-10-01 | 2021-07-27 | Adicet Bio, Inc. | composições e métodos relativos a células t¿d engenheiradas e não engenheiradas para tratamento de tumores sólidos |
| EP3870600A1 (en) | 2018-10-24 | 2021-09-01 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| WO2020097346A1 (en) * | 2018-11-07 | 2020-05-14 | Unum Therapeutics Inc. | ANTI-GPC3 CHIMERIC ANTIGEN RECEPTORS (CARs) IN COMBINATION WITH TRANS CO-STIMULATORY MOLECULES AND THERAPEUTIC USES THEREOF |
| EP3894011B1 (en) | 2018-12-11 | 2025-09-17 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| WO2020127513A1 (en) * | 2018-12-19 | 2020-06-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Mucosal-associated invariant t (mait) cells expressing chimeric antigen receptors |
| KR20210149251A (ko) | 2019-03-08 | 2021-12-08 | 옵시디안 테라퓨틱스, 인크. | 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법 |
| JP7585228B2 (ja) * | 2019-04-04 | 2024-11-18 | 上海医薬集団股▲フン▼有限公司 | 腫瘍抗原認識受容体を有する免疫細胞とその応用 |
| JP2022537670A (ja) | 2019-06-12 | 2022-08-29 | オブシディアン セラピューティクス， インコーポレイテッド | Ｃａ２の組成物および調整可能な制御方法 |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| WO2020257823A2 (en) | 2019-06-21 | 2020-12-24 | Kite Pharma, Inc. | TGF-β RECEPTORS AND METHODS OF USE |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| KR20250154516A (ko) * | 2020-03-18 | 2025-10-28 | 주식회사 유틸렉스 | Il-18을 분비하는 gpc3 car-t 세포 및 이의 제조 및 사용 방법 |
| CN115667500A (zh) * | 2020-03-18 | 2023-01-31 | 优特力克斯有限公司 | Gpc3 car-t细胞组合物及其制备和使用方法 |
| CN116490518A (zh) | 2020-07-17 | 2023-07-25 | 西穆尔克斯股份有限公司 | 用于重定向免疫抑制信号传导的嵌合MyD88受体及相关组合物和方法 |
| CN112225822B (zh) * | 2020-12-14 | 2021-03-23 | 北京基因启明生物科技有限公司 | 高扩增、存续能力和杀瘤作用的CAR-iNKT及应用 |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN117545771A (zh) | 2021-04-08 | 2024-02-09 | 克莱格医学有限公司 | 细胞免疫治疗的应用 |
| WO2023091909A1 (en) | 2021-11-16 | 2023-05-25 | Sotio Biotech Inc. | Treatment of myxoid/round cell liposarcoma patients |
| CN117230174A (zh) * | 2023-04-03 | 2023-12-15 | 上海交通大学医学院附属瑞金医院 | Gpc3在诊断特发性肺纤维化中的应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| ES2373055T3 (es) * | 2005-08-09 | 2012-01-31 | Oncotherapy Science, Inc. | Péptido antígeno de rechazo de cáncer derivado de glipican-3 (gpc3) para uso en pacientes positivos a la hla-a2 y producto farmacéutico que comprende el antígeno. |
| ES2666550T3 (es) | 2011-04-19 | 2018-05-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticuerpos monoclonales humanos específicos para glipicano 3 y uso de los mismos |
| EP2755487B1 (en) * | 2011-09-16 | 2018-12-19 | Baylor College Of Medicine | Targeting the tumor microenvironment using manipulated nkt cells |
| WO2013070468A1 (en) * | 2011-11-08 | 2013-05-16 | The Trustees Of The University Of Pennsylvania | Glypican-3-specific antibody and uses thereof |
| WO2014138314A1 (en) * | 2013-03-05 | 2014-09-12 | Baylor College Of Medicine | Oncolytic virus |
| CN104140974B (zh) * | 2013-05-08 | 2017-09-29 | 科济生物医药（上海）有限公司 | 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞 |
| DK3333192T3 (da) * | 2015-08-03 | 2021-05-31 | Cafa Therapeutics Ltd | Antistof imod glypican-3 og anvendelse deraf |
-
2015
- 2015-09-25 ES ES20196219T patent/ES2851123T1/es active Pending
- 2015-09-25 EP EP15845117.9A patent/EP3198010B1/en active Active
- 2015-09-25 WO PCT/US2015/052227 patent/WO2016049459A1/en not_active Ceased
- 2015-09-25 EP EP20196219.8A patent/EP3858991A1/en active Pending
- 2015-09-25 DE DE20196219.8T patent/DE20196219T1/de active Pending
- 2015-09-25 JP JP2017516350A patent/JP2017529851A/ja active Pending
- 2015-09-25 US US15/513,900 patent/US20170281683A1/en not_active Abandoned
- 2015-09-25 ES ES15845117T patent/ES2844700T3/es active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017529851A5 (enExample) | ||
| Mizukoshi et al. | Immune cell therapy for hepatocellular carcinoma | |
| JP2021506243A5 (enExample) | ||
| IL292650A (en) | Chimeric antigen receptor T cells target il13ra2 | |
| RU2018113510A (ru) | Химерные рецепторы антигена, нацеленные на psca | |
| RU2018107802A (ru) | Полностью человеческие антитела к мезотелину и иммунные эффекторные клетки, нацеленные на мезотелин | |
| JP2016534717A5 (enExample) | ||
| JP2019528769A5 (enExample) | ||
| HRP20211978T1 (hr) | Kimerični antigenski receptori koji ciljaju receptor spojen na g-protein i njihove uporabe | |
| JP2017513478A5 (enExample) | ||
| JP2016502512A5 (enExample) | ||
| RU2017121826A (ru) | Т-клетки, модифицированные химерным рецептором антигена, нацеленным на cs1 | |
| JP2019500894A5 (enExample) | ||
| JP2017522862A5 (enExample) | ||
| JP2018506981A5 (enExample) | ||
| MY186846A (en) | Method and compositions for cellular immunotherapy | |
| JP2017518037A5 (enExample) | ||
| JP2016508728A5 (enExample) | ||
| RU2018105963A (ru) | Антитело против глипикана-3 и его применение | |
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| WO2017011804A8 (en) | Engineered cells for adoptive cell therapy | |
| EP4537839A3 (en) | Method and compositions for cellular immunotherapy | |
| JP2017538401A5 (enExample) | ||
| JP2015509717A5 (enExample) | ||
| JP2019521704A5 (enExample) |